

# News Releases

All Years



Search

GO

[Advanced Search](#)

**Nov 15, 2019**

## **Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians**

**- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...

**Nov 6, 2019**

## **Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting**

**- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...

**Nov 5, 2019**

## **Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update**

**- Andexxa®/Ondexxa® Net Product Revenues of \$35.7 million, a 32% Increase Over the Prior Quarter -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...

**Nov 1, 2019**

## **Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant...

**Oct 28, 2019**

## **Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding**

**- Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b/4 trial of its Factor Xa inhibitor...



**Oct 15, 2019**

## **Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019,...

**Sep 19, 2019**

**Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors**

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...

**Aug 22, 2019**

**Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

**Aug 13, 2019**

**Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock**

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of \$28.00 per share. In...

**Aug 12, 2019**

**Portola Pharmaceuticals Announces Proposed Offering of Common Stock**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, \$200 million of its common stock in an underwritten public offering. The...

**Aug 7, 2019**

**Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update**

- **Second Quarter Revenues of \$28.4 Million; Andexxa® Net Product Revenues Grow to \$27.1 Million**  
-

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update. "This is our fifth consecutive quarter of...

**Aug 6, 2019**

**Portola Launches European Sales of Ondexxa® (Andexanet Alfa) with First Orders in Europe**

- **Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban** -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxa® (andexanet alfa) in Europe. These sales mark the initiation of commercial access in Europe to...

**Aug 5, 2019**

**U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa**

- **Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting** -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology...

**Jul 17, 2019**

**Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...

**Jul 8, 2019**

**Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors**

**- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...

**Jun 19, 2019**

**Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma**

**- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

**May 28, 2019**

**Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences**

May 28, 2019 PDF Version SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and...

**May 22, 2019**

**Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage**

**- Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage -**

SOUTH SAN FRANCISCO, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new analysis of data from an important subgroup...

**May 8, 2019**

**Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update**

**- First Quarter Revenues of \$22.2 Million; Andexxa® Product Revenues Grow 45% to \$20.3 Million -**

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2019 and...

**Apr 26, 2019**

**European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxa™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors**

**- Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding -**

SOUTH SAN FRANCISCO, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing...

**Apr 24, 2019**

**Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development**

SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that John Curnutte, M.D., Ph.D., Executive Vice President and Head of...

**Apr 17, 2019**

**Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019**

SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company'

**Mar 20, 2019**

**Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors**

SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...

**Mar 6, 2019**

**Portola Pharmaceuticals to Webcast Presentation at Cowen and Company's 39th Annual Health Care Conference**

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and chief executive...

**Mar 1, 2019**

**European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals' Factor Xa Inhibitor Reversal Agent**

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Show 25  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) 



<https://investors.portola.com/news-releases?l=25>